European carmakers are urging Brussels to ease regulations to help them avoid buying carbon credits from rivals in increasingly large amounts.

BMW and Tesla have both filed cases with the European Union’s (EU) Court of Justice challenging the EU’s recent decision to hike tariffs on Chinese-made battery electric vehicles (BEVs). The two automakers join a long list of Chinese automakers that have filed similar lawsuits against the EU,

The Detroit carmaker is creating a domestic supply base to make EVs cheaper and profitable aided by Kurt Kelty, who landed Tesla’s top battery supplier in its early days.

Tesla Inc (NASDAQ: TSLA) shares surged 4% in after-hours trading despite missing Wall Streets fourth-quarter revenue estimates. The electric vehicle (EV) giant reported revenue of $25.71 billion, below

The European stock markets closed mixed in Monday trading as The Stoxx Europe 600 was off 0.04%, Germany's DAX declined 0.54%, the FTSE 100 in London edged 0.02% higher, France's CAC 40 was down 0.27%,

Tesla (NASDAQ: TSLA) announced plans to roll out new, more affordable electric vehicles (EVs) in early 2025 while launching an autonomous ride-hailing service in June. Despite missing Wall Street revenue expectations,

Tesla expects capital expenditure to exceed $11 billion this year and in each of the following two fiscal years, the electric automaker said in a filing on Thursday.

Under stricter European Union regulations taking effect this year, automakers selling cars in Europe face large penalties if their vehicle

Tesla, owned by Elon Musk, is taking the European Union (EU) to court over its tariffs on electric vehicles imported from China. Filed last Wednesday with the European Court of Justice (ECJ) by Tesla’s Shanghai division, the lawsuit comes in the wake of similar legal moves by BMW and other Chinese car manufacturers.

Tesla stock was trying to avoid a third consecutive day of declines as investors weighed what big price increases for Tesla’s most popular cars in Canada mean for overall EV pricing and demand in 2025.

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD) in the European Union.